Literature DB >> 23735062

Comparison of double disk synergy test, VITEK 2 and Check-MDR CT102 for detection of ESBL producing isolates.

Fatima Numanovic1, Mirsada Hukic, Zineta Delibegovic, Nijaz Tihic, Selma Pasic, Merima Gegic.   

Abstract

OBJECTIVE: This study is to define the statistical significance for detection of ESBL producers by the double disk synergy test and molecular test (Check-MDR CT102), microdilution test (VITEK 2 with AES) and double disk synergy test (DDST), as well as the microdilution test and molecular test.
MATERIALS AND METHODS: Phenotypic testing of 55 isolates Enterobacteriaceae (Escherichia coli (14/55), Klebsiella pneumoniae (34/55), Klebsiella oxytoca (3/55) and Proteus mirabilis (4/55) was performed by VITEK 2 Compact/AES. When this test showed positive results for the ESBL phenotype, then DDST with amoxicillin/clavulanate, ceftazidime, cefpodoxime, aztreonam, ceftriaxone and cefoxitin disks was performed along with Check-MDR CT102 which identified CTX-M, TEM and SHV β-lactamases.
RESULTS: Applying the McNemar test, we determined that there was a statistically significant difference in the results of detection of ESBLs bacteria using DDST compared to molecular methods (95% CI=41.92 to 54.55; p<0.0001), as well as a DDST and VITEK 2/AES (95% CI=40.13 to 52.73; p<0.0001). We did not find any statistically significant difference in the results of detection of ESBL producers using molecular techniques and VITEK 2/AES (CI=-4,43 to 5,36; p=1). Also we did not find any statistical.. difference between the resistance to cefpodoxime and ceftriaxone (50/50) compared to the results of molecular tests.
CONCLUSION: In routine daily testing, good detection of ESBLs bacteria, especially CTX-M can be obtained with phenotypic methods with VITEK 2/AES and by DDST with cefpodoxime, and ceftriaksone disks.
Copyright © 2013 by Academy of Sciences and Arts of Bosnia and Herzegovina.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23735062     DOI: 10.5644/ama2006-124.66

Source DB:  PubMed          Journal:  Acta Med Acad        ISSN: 1840-1848


  2 in total

1.  Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.

Authors:  Mohammad Al-Tamimi; Hadeel Albalawi; Marwan Shalabi; Jumana Abu-Raideh; Ashraf I Khasawneh; Farah Alhaj
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-05-22       Impact factor: 6.781

2.  Clinical Response and Outcome in Patients with Multidrug Resistant Gram-negative Infections.

Authors:  Masoume Malekolkottab; Lida Shojaei; Hossein Khalili; Mahsa Doomanlou
Journal:  J Res Pharm Pract       Date:  2017 Jan-Mar
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.